[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"joint-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:joint-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,101,139,165,197,224,249,283],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100525557","early-phase-1-tart-cherry-and-omega-3s-for-aromatase-inhibitor-musculoskeletal-symptoms-100525557",false,"NCT06123286","Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms","An Open Label, Randomized, Waitlist Controlled Trial of Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms","Inclusion Criteria:\n\n* Breast cancer diagnosis (Stage I-III) with any hormonal status.\n* Females aged ≥ 18 years.\n* Currently receiving AI therapy.\n* BMI ≥ 27.\n* Clinical diagnosis of AIMSS.\n* Omega-3 Index \\<8%.\n* Average joint pain score ≥ 4 on the Brief Pain Inventory (BPI) within 7 days of enrollment.\n* Written informed consent obtained from subject and ability and willingness of subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Current use of anticoagulant medications (Including but not limited to Warfarin, Lovenox, Eliquis, Xarelto).\n* Allergy to cherries or fish\u002Ffish products.\n* Lifetime history of rheumatoid arthritis and\u002For inflammatory joint diseases (Including but not limited to reactive arthritis, ankylosing spondylitis, and psoriatic arthritis).\n* Uncontrolled diabetes mellitus as determined by treating physician (with or without the use of glucose lowering medications and\u002For insulin).\n* Lifetime history of stroke or transient ischemic attacks.\n* New use or dose change of oral or topical analgesics in the previous 14 days. (Including but not limited to opioids, non-steroidal anti-inflammatories, acetaminophen, SNRI's, SSRI's, gabapentinoids, tricyclic antidepressants, and muscle relaxants).\n* Oral or intra-articular steroid use in the previous 30 days (Including but not limited to dexamethasone, prednisone, methylprednisolone, triamcinolone, hydrocortisone).\n* History of joint fracture or surgery of the symptomatic joint in the previous 6 months.","FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. Further, both Tart Cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addition to other health issues like insomnia.\n\nThere is preliminary evidence in mouse models that when given together, these supplements may have an even greater anti-inflammatory effect than when taken separately14. Although to our knowledge, no human studies have tested this hypothesis. This study has been designed to test the hypothesis that Tart Cherry and fish oil when given in combination over a 12-week period could produce beneficial changes in joint function when compared to Tart Cherry or fish oil in isolation in an obese breast cancer population experiencing AIMSS. Secondary outcomes to be assessed include pain, functional performance, quality of life and cognition.",[26,27,28],"Breast Cancer","Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)","Joint Pain",[30,31,27,32,33,34,35],"Aromatase Inhibitor Therapy","AIMSS","Tart Cherry","Omega 3 Fatty Acids Fish Oil","Female Breast Cancer","Aromatase Inhibitor Arthralgia","RECRUITING","2026-05-01",{"date":39,"type":40},"2026-05-05","ACTUAL",{"date":42,"type":40},"2025-09-12",{"date":44,"type":20},"2027-10",{"name":46,"class":47},"Philip Chang","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":62,"conditions":63,"keywords":70,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100489857","phase-2-study-of-dapansutrile-tablets-in-subjects-with-an-acute-gout-flare-100489857","NCT05658575","Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","A Multi-Center Phase 2\u002F3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","Inclusion Criteria:\n\n* Male and female subjects age 18 or older\n* Clinical diagnosis of gout according to the 2015 ACR\u002FEULAR Gout Classification Criteria:\n\nA) Diagnosis of gout must be confirmed in the target joint as indicated by either the presence of monosodium urate (MSU) crystals by microscopic evaluation of synovial fluid from the target joint or bursa OR by imaging evidence of urate deposition in the target joint or bursa at the Screening\u002FBaseline Visit\u002FStudy Day 1, or\n\nB) Documented history in the target joint or bursa ; or documented history of 2 or more gout flares in the previous 18 months\n\n* Confirmation of a gout flare in the target joint that began within 96 hours prior to the Screening\u002FBaseline Visit\n* Provide written informed consent and understand and comply with all trial requirements\n\nExclusion Criteria:\n\n* Presence of any palpable and visible tophi by physical examination\n* Has ≥ 4 joints with an acute gout flare at Screening\u002FBaseline\n* Presence of active rheumatoid arthritis or other acute inflammatory arthritis\n* Evidence\u002Fsuspicion of infectious\u002Fseptic arthritis\n* Clinically significant general pain or non-gout-related joint pain that would interfere with the subject's ability to accurately assess pain in the target joint\n* Known diagnosis of chronic kidney disease or known history of renal impairment\n* Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection, if tested, within 4 weeks of the Screening\u002FBaseline\n* Active malignancy or recent malignancy with any systemic anti-cancer treatment\n* Has a hypersensitivity or allergy to OLT1177® or other drugs in its class\n* Hypersensitivity or allergy to paracetamol\u002Facetaminophen\n* Use of any prohibited concomitant medications\u002Ftherapies over the periods defined in the protocol or planned use of any prohibited concomitant medications\u002Ftherapies during the Treatment Period (including the use of paracetamol\u002Facetaminophen within 4 hours prior to the Screening\u002FBaseline Visit or other pain medications within 12 hours prior to the Screening\u002F Baseline Visit\n* Use of any product containing paracetamol\u002Facetaminophen within 4 hours prior to the Screening\u002FBaseline Visit or planned use during the Treatment Period (with the exception of study-provided Rescue Medication \\[paracetamol\u002Facetaminophen\\], which is permitted after completion of the first target joint pain assessment on Study Day 4","ALL",{"count":58,"type":20},300,[60,61],"PHASE2","PHASE3","The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.",[64,65,66,67,68,69,28],"Acute Gout Flare","Gout Attack","Gout Flare","Gouty Arthritis","Gout","Arthritis",[71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89],"gout","gouty arthritis","mono-articular arthritis","NLRP3","NLRP3 inhibitor","dapansutrile","OLT1177","joint pain","inflammation","gouty Inflammation","inflammasomes","IL-1 beta","IL-1 inflammation","autoinflammatory conditions","hyperuricemia","uric acid crystal","flare","small-molecule","therapeutic","2026-03-09",{"date":92,"type":40},"2026-03-11",{"date":94,"type":40},"2023-01-06",{"date":96,"type":20},"2027-01-31",{"name":98,"class":99},"Olatec Therapeutics LLC","INDUSTRY",40,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":16,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100611276","jds-hf30-supplementation-on-menopause-related-quality-of-life-outcomes-in-postmenopausal-women-100611276","NCT07238478","JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women","Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of JDS-HF3.0 in Menopause Related Quality of Life Outcomes in Postmenopausal Women","Inclusion Criteria:\n\n1. Healthy biological females who are 50-70 years of age (inclusive).\n2. Have a body mass index (BMI) between 18.5 to 34.9 kg\u002Fm2 (inclusive).\n3. Self-reported as postmenopause. Defined as 12 months without a menstrual cycle in individuals who undergo \"Natural\" Menopause (Not Surgically or medically induced) and who have self-reported menopausal outcomes for the past 6 months.\n4. Have self-reported menopause related joint outcomes of moderate or severe severity according to a perceived discomfort greater or equal to 5 and less than 10 on a scale of 0-10 (participants rating their discomfort 5-9 will be included).\n5. Have self-reported \\> or equal to 4 hot flashes on average per day.\n6. In good general health (no active or uncontrolled diseases or conditions) and able to consume the study product.\n7. Agree to refrain from treatments listed in Section 6.5 in the defined timeframe.\n8. Have reliable, stable access to Wi-Fi and a smart phone\u002Fdevice.\n9. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read questionnaires, and carry out all study-related procedures.\n\nExclusion Criteria:\n\n1. Individuals who are lactating, pregnant, or planning to become pregnant during the study.\n2. Active participation in a clinical trial.\n3. Use of any treatment for menopausal outcomes or other concomitant treatments for menopausal symptoms, joint health or at the discretion of the investigator. (Participants may be deemed ineligible at the discretion of the investigator if the medication may cause adverse interaction.)\n4. Have a known sensitivity, intolerability, or allergy to any of the study product or their excipients.\n5. Use of Glucosamine and\u002For Chondroitin for joint outcomes in the last 3 months prior to screening.\n6. Received a COVID-19 vaccine in the 2 weeks prior to screening or during the study period, current COVID-19 infections or currently have the post-COVID-19 condition as defined by World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least two months and cannot be explained by an alternative diagnosis).\n7. Have a positive medical history of heart disease, renal disease, hepatic impairment, or active systemic infection (i.e., Lyme disease, TB, HIV).\n8. History of cancer (except localized skin cancer without metastases) within two (2) years prior to screening.\n9. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study or influence the results or the potential subject's ability to participate in the study.\n10. History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (i.e., Crohn's disease, short bowel, acute or chronic pancreatitis, gastric bypass procedures, or pancreatic insufficiency).\n11. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea).\n12. Major surgery in three months prior to screening or planned major surgery during the study.\n13. History of alcohol or substance abuse in the last 5 years.\n14. Has evidence of inflammatory rheumatic disease or other diagnosed anti-inflammatory disease.\n15. Has evidence of autoimmune disease(s).\n16. Chronic use of curcumin or curcuminoids in an herbal or dietary supplement. Note: Screened participants that are willing to undergo a washout period of at least 3 months prior to participation in the trial can be enrolled.\n17. Chronic pain medication and use of analgesics specifically for joint-related discomfort (i.e. Opiates, Tramadol) Note: Screened participants that are willing to undergo a washout period of at least 2 weeks during the duration of the trial can be enrolled.\n18. Have severe joint and\u002For severe bone deformities.\n19. Diagnosed bone fractures.\n20. Are a candidate for surgical joint replacement.",true,"50 Years","70 Years",{"count":112,"type":20},250,[114],"NA","The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70. The primary research question is whether taking the study product daily for 12 weeks can reduce the severity and frequency of menopause-related symptoms.",[117,118,28,119,120,121,122],"Joint Discomfort","Joint Pain, Stiffness, Function","Hot Flashes","Hot Flash","Night Sweats","Vasomotor Symptoms",[124,125,122,126,119,28,117,127,128],"Postmenopausal","Post menopause","Night sweats","Non-hormonal Treatment","Supplement","2025-11-18",{"date":131,"type":40},"2025-11-20",{"date":133,"type":40},"2025-05-14",{"date":135,"type":20},"2026-10",{"name":137,"class":99},"Bonafide Health",1,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":56,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":138},"100579735","dietary-wild-blueberries-and-joint-health-100579735","NCT06828159","Dietary Wild Blueberries and Joint Health","Effects of Dietary Wild Blueberries on Gut Health and Inflammation and Joint Pain","Inclusion Criteria:\n\n* Adults with documented multi-joint\u002Fknee arthritis\n\nExclusion Criteria:\n\n* inability to give informed consent\n* pregnancy or lactation\n* planned knee replacement surgery\n* allergy or contraindication to berries\n* recent trauma of the knee responsible of the symptomatic knee\n* intra-articular injection in the target knee\u002Fhip in the last 3 months\n* oral corticosteroid therapy ≥ 5 mg\u002Fday (prednisone equivalent) at baseline\n* use of berry extracts in the last 3 months\n* special diets\n* cancer treatment\n* bone diseases","40 Years","75 Years",{"count":149,"type":20},50,[114],"The goal of this proposed study is to examine the effects of dietary wild blueberries on gut microbiome, serum markers of inflammation, and joint function in adults. Each participant will consume 25g freeze-dried blueberries or matched placebo powder for 12 weeks, with a 2-week washout phase between.",[153,154,155,28],"Gut -Microbiota","Inflammation Biomarkers","Pain Assessment","2025-11-03",{"date":158,"type":40},"2025-11-05",{"date":160,"type":40},"2025-09-01",{"date":162,"type":20},"2028-03",{"name":164,"class":47},"University of Nevada, Las Vegas",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100606704","evaluating-the-auricular-point-acupressure-self-management-program-for-chronic-musculoskeletal-pain-among-rural-populations-100606704","NCT07179016","Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations","A Pragmatic, Randomized Controlled Trial of a Auricular Point Acupressure - Self-Management (APA-SM) Program for Chronic Musculoskeletal Pain Among Rural Populations.","Inclusion Criteria:\n\n* Receive any pain management for CMP (neck, back, shoulder, hands, hips, knees, feet)\n* Have CMP ≥ 4 on a scale of 0-10 that has persisted for at least 3 months or has resulted in pain on at least half the days in the past 6 months\n\nExclusion Criteria:\n\n* Severe ear skin disorder (Diagnosed with conditions e.g., eczema, lupus with skin involvement) which often require medical intervention and severe allergy to tape\n* Inability or unwillingness to provide informed consent\n* Use of some type of hearing aid where size may obstruct seed placement\n* Not living in rural area","85 Years",{"count":174,"type":20},693,[114],"The investigators will test an Auricular Point Acupressure Self-Management (APA-SM) program integrated into rural primary and specialty care and rural communities for chronic musculoskeletal pain (CMP). To maximize self-management of pain, the investigators developed a smartphone app which will allow the participants to learn to self-administer APA. The investigators will have 3 arms (APA-SM self-guided with remote training, APA-SM with in-person training, and Education Control) with 231 participants per arm (total=693 for 3 arms). The investigators will evaluate the clinical effectiveness of our 4-week APA-SM intervention compared to control in primary outcomes (pain intensity, pain interference, activity), secondary outcomes (HEAL Clinical Pain Core common data elements), and analgesic use up to 6 months follow-up.",[178,179,180,28],"Chronic Pain (Back \u002F Neck)","Chronic Pain Management","Chronic Knee Pain",[182,183,184,185,186],"Chronic Pain","Rural population","Self-management","Chronic musculoskeletal pain","Auricular point acupressure","2025-09-24",{"date":189,"type":40},"2025-10-01",{"date":191,"type":40},"2025-09-11",{"date":193,"type":20},"2029-08-31",{"name":195,"class":47},"The University of Texas Health Science Center, Houston",3,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":56,"minAge":146,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":138},"100582463","phase-3-efficacy-and-safety-of-celecoxibacetaminophen-versus-celecoxib-for-diagnosed-osteoarthritis-in-acute-exacerbation-100582463","NCT06863636","Efficacy and Safety of Celecoxib\u002FAcetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation","Efficacy and Safety Study of the Fixed-dose Combination of Celecoxib\u002FAcetaminophen Compared to Celecoxib for the Treatment of Pain in Patients Diagnosed With Osteoarthritis in Acute Exacerbation","PRECEDENT","Inclusion Criteria:\n\n* Voluntarily agrees to participate in the study and provides written informed consent.\n* Prior diagnosis of knee or hip osteoarthritis based on clinical criteria (according to the American College of Rheumatology (ACR) criteria described in Annex 5).\n* Pain in the affected joint with exacerbation lasting no more than 3 weeks.\n* Patient reports moderate to severe pain intensity (VAS ≥ 40 mm).\n* For women of childbearing potential (a woman is considered fertile after menarche and until postmenopause unless permanently sterile), they must agree to use at least ONE of the following contraceptive methods during the study:\n\nBarrier methods: diaphragm, cervical cap, male condom, female condom, spermicide foam, sponge, or film.\n\nHormonal methods: combined oral contraceptives, injectable contraceptives, subdermal implant, contraceptive patch.\n\nIntrauterine device (IUD): copper or silver IUD, Levonorgestrel intrauterine system (IUS), and\u002For combinations of the above as deemed acceptable by the physician.\n\nWomen are considered not of childbearing potential if they meet at least ONE of the following criteria:\n\nPostmenopausal. Premenopausal woman with at least ONE of the following: hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.\n\nMale subjects must agree to use a male condom as a contraceptive method during the study.\n\n* At the discretion of the Principal Investigator (PI) or treating physician, the subject has an indication for treatment with the investigational product and may derive clinical benefit from it.\n\nExclusion Criteria:\n\n* Intolerance or allergy to the investigational product or any of its components (as reported in the medical history and patient interview).\n* Participation in another clinical study involving an investigational treatment or participation in one within the last two weeks prior to the study start.\n* Potential study bias due to employment or relationship with the research center, sponsor, or being part of a vulnerable population.\n* Medical conditions affecting prognosis that prevent outpatient management, to be evaluated by the Principal Investigator for subject inclusion relevance.\n* History of advanced, severe, progressive, or unstable disease of any kind that may interfere with efficacy and safety assessments or pose a special risk to the patient.\n* Medical contraindication to the investigational product.\n* History of allergic reaction to NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Acetaminophen, or known hypersensitivity to any formulation components.\n* Significant gastrointestinal disorders, such as gastric ulcers, Crohn's disease, ulcerative colitis, or gastrointestinal bleeding.\n* Prior opioid treatment within the last five days, as reported in the medical history.\n* History of treatment failure with COX-2 selective inhibitors, as documented in the medical history.\n* History of chronic somatic pain unrelated to knee or hip osteoarthritis (e.g., fibromyalgia, metastatic disease, or Paget's disease).\n* History of alcohol or drug abuse within the past year.\n* Current treatment with NSAIDs, including COX-2 inhibitors, within the last 72 hours before signing informed consent (except for aspirin used for cardioprotective purposes).\n* History of arthroscopy, viscosupplementation, or intra-articular steroid use in the last three months.\n* Previous surgery on the affected joint within the last six months.\n* Major trauma in the affected joint within the last three weeks.\n* History of chronic liver failure (Child-Pugh A, B, or C).\n* History of acute or severe renal failure (glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m²), as reported in the medical history.\n* Significant coagulation disorders (e.g., Von Willebrand disease, hemophilia, vitamin K deficiency) or current use of anticoagulants.\n\nOncologic patients (except basal cell carcinoma) or those with severe illnesses that, according to the investigator, have a poor prognosis or a life expectancy of less than one year, including severe mental illness.\n\n* Patients with symptoms suggestive of active COVID-19 infection (e.g., fever, cough, dyspnea) and\u002For contact within the last 14 days with a suspected or confirmed COVID-19 patient.\n* Positive pregnancy test, pregnant women, those currently breastfeeding, or those planning pregnancy during the study period.",{"count":206,"type":20},231,[61],"This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial designed to evaluate the efficacy and safety of a fixed-dose combination of celecoxib and acetaminophen compared to celecoxib monotherapy for the treatment of pain associated with acute exacerbations of osteoarthritis.",[28,210,211],"Knee Osteoarthritis","Hip Osteoarthritis",[213,210,211,214],"Joint pain","Acute pain","2025-04-01",{"date":217,"type":40},"2025-04-04",{"date":219,"type":40},"2024-09-09",{"date":221,"type":20},"2025-11-30",{"name":223,"class":99},"Laboratorios Silanes S.A. de C.V.",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":56,"minAge":4,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":239,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100582521","genicular-nerve-phenol-neurolysis-versus-radiofrequency-ablation-for-pain-relief-in-grade-4-knee-osteoarthritis-100582521","NCT06864390","Genicular Nerve Phenol Neurolysis Versus Radiofrequency Ablation for Pain Relief in Grade 4 Knee Osteoarthritis","Inclusion Criteria:\n\n* Grade 4 knee osteoarthritis according to Kellgren-Lawrence radiological classification.\n* Failure to manage pain with conservative methods.\n\nExclusion Criteria:\n\n* Prior knee replacement\n* Patients with cardiac pacemakers or implantable cardiac defibrillators.\n* Septic knee or systemic sepsis.\n* Allergy to any of the drugs used in the study.\n* Coagulopathy or patients on anticoagulants.\n* Patients with psychiatric illness.",{"count":231,"type":20},114,[114],"The goal of this clinical trial is to compare the efficiency and efficacy of genicular nerves blockade by chemical phenol neurolysis versus radiofrequency ablation in managing pain in patients suffering from grade IV KOA in term of NRS pain score.\n\nThe participants will be evaluated by numeric rating scale and oxford knee score for assessment of pain relief up to 16 weeks.",[28],[236,237,238],"phenol neurolysis","radiofrequency","Knee osteoarthritis","NOT_YET_RECRUITING","2025-03-06",{"date":242,"type":40},"2025-03-07",{"date":244,"type":20},"2025-04",{"date":246,"type":20},"2025-11",{"name":248,"class":47},"Ain Shams University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":108,"sex":16,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":268,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":138},"100556849","phase-2-the-muse-study-for-menopausal-arthralgia-100556849","NCT06530459","The MUSE Study for Menopausal Arthralgia","The MUScle Strengthening Exercises and Estrogen (MUSE) Randomized Controlled Trial for Menopausal Arthralgia","MUSE","INCLUSION CRITERIA:\n\n1. Patients with muscle stiffness and joint discomfort in various sites, including hands, knees, back, hips, and\u002For shoulders. Patients with pain in only one isolated joint would not be accepted.\n2. Arthralgia symptoms with onset, or has become worse, over the perimenopausal or early postmenopausal period (within 5 years of the menopause).\n3. Women should be at the menopause transition, less than or equal to 59 years old at the time of enrollment, or within 5 years of menopause whichever is earlier.\n\n   .\n4. Arthralgia for at least 3 months (pain lasting beyond normal injury healing period)\n5. Community-dwelling and able to ambulate independently.\n\nEXCLUSION CRITERIA:\n\n1. History of thrombo-embolic diseases, strokes, ischemic heart disease, dementia or psychiatric disorders, active liver disease or renal impairment, severe hyperlipidemia, gout, thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, or other chronic inflammatory conditions.\n2. Pregnancy\n3. Non-adherence to national guidelines for breast cancer screening\n4. High risk for breast cancer\n5. Any joint surgery within the last 6 months\n6. Severe obesity: BMI\\>35\n7. Migraine with aura\n8. Poorly controlled diabetes\n9. Use of any form of female hormone supplementation within the past 12 weeks.\n10. High venous thromboembolism risk\n11. Current cholecystitis, fibroids, or undiagnosed abnormal uterine bleeding.\n12. Current smoker.\n13. History of endometrial, ovarian, peritoneal, cervical, breast or endocrine-dependent cancers.\n14. Receiving treatment for any form of cancer.\n15. History of fragility bone fractures within the 2 years.\n16. Any other cognitive, musculoskeletal, neurological, and cardiorespiratory condition affecting one's ability to participate in the study.","30 Years","59 Years",{"count":260,"type":20},100,[60,61],"The investigators plan to conduct a pilot 4-arm, randomized study comprising the following interventions: muscle strengthening exercises (MSE) alone, estrogen therapy (ET) alone, and a combination of MSE and ET, compared to usual care in women with menopausal arthralgia. The aim of this pilot study is to assess the feasibility, patient acceptability, and patient perspectives and logistics of delivering interventions, and practicability of outcome assessment tools in this 4-arm study over a 12-week period.",[264,265,266,28,267],"Arthralgia","Menopause","Perimenopausal Disorder","Postmenopausal Disorder",[269,270,271,272,273],"Menopausal hormone therapy","Muscle strength","Exercise","Randomized controlled trial","Midlife women","2024-07-26",{"date":276,"type":40},"2024-07-31",{"date":278,"type":20},"2024-08-01",{"date":280,"type":20},"2028-04",{"name":282,"class":47},"National University Hospital, Singapore",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":21,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":138},"100521834","subsartorial-nerve-block-and-femoral-nerve-block-in-total-knee-arthroplasty-100521834","NCT06074744","Subsartorial Nerve Block and Femoral Nerve Block in Total Knee Arthroplasty","Subsartorial Saphenous Nerve Block (SSNB) Versus Femoral Nerve Block (FNB) in Primary Total Knee Arthroplasty (TKA) Combined With Infiltration Between Popliteal Artery and Capsule of the Knee (IPACK) - Where Are the Benefits?","Inclusion criteria:\n\n* age \\> 18yrs\n* primary TKA\n* BMI 35kg\u002Fm2 or less\n* able to give informed consent as documented by signature\n* clinical history without any contraindications for the planned intervention\n\nExclusion criteria:\n\n* age \\\u003C 18 years\n* revision-TKA\n* BMI \\>35kg\u002Fm2\n* absent contact information\n* inability or contraindications to undergo the investigated intervention (TKA, FNB, SSNB), - clinically significant concomitant diseases\n* pregnancy\n* inability to follow the procedures and follow-up procedures of the study (e.g. due to language problems, psychological disorders, dementia, living abroad, etc.\n* withdrawal from the study",{"count":291,"type":20},144,[114],"The goal of this clinical trial is to compare two different types of nerve blocks in patients undergoing surgery for primary Total Knee Arthroplasty. The main question aim to answer is:\n\n\\- is there a benefit in functional muscle power output of the leg?\n\nParticipants will be randomized into either the intervention group or the control group and:\n\n* receive Subsartorial Saphenous Nerve Block (SSNB) + IPACK in intervention group (group 1)\n* receive Femoral Nerve Block (FNB) + IPACK in control group (group 2)\n\nResearchers will compare the 2 groups to see if there are differences in :\n\n* functional muscle power output of the leg?\n* muscle function, mobility, clinical and radiological results, ROM, pain control (NRS), opioid consumption, length of hospital stay, patient satisfaction, mobility, reduction of costs?",[295,28],"Joint Diseases",[297,298,299],"Subsartorial Saphenous Nerve Block (SSNB)","Femoral Nerve Block (FNB)","Total Knee Arthroplasty (TKA)","2024-03-07",{"date":302,"type":40},"2024-03-12",{"date":304,"type":40},"2023-11-30",{"date":306,"type":20},"2026-12",{"name":308,"class":47},"Luzerner Kantonsspital"]